NASDAQ · TRDA

Entrada Therapeutics, Inc.

Healthcare · Biotechnology

$6.75▼ 2.17% ($0.15)at close

As of 4:00 PM ET

52-week

$5.08$16.45

Market cap

$262.04M

P/E

-1.70

EPS (TTM)

-$3.93

Next earnings

Nov 5, 2026

No multiple

What the market price implies · Reverse DCF

Historical revenue grew by -55.61%/yr over the past 2 years.

Selected forecast · Base scenario

0.8%/yr · actual 10-year annualized revenue growth

Year 1 growth: 0%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$6.75

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.

Only 3 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.

Year 1 growth 0% · Ending margin 0% · Discount rate 7.75%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 18, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 20, 2026, 6:24 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Momentum disconnected from fundamentalsModerate confidence

1Y Price: 21.62%Revenue (TTM): -94.1%FCF (TTM): -6.16%P/S: 86th pct

What changed

The stock rose 21.62% over the last year. Revenue declined 94.1% over the trailing twelve months. Operating margin moved from -121% to -3,767.07%. Free cash flow declined 6.16% over the trailing twelve months.

What the market seems to be pricing

The stock is rising despite deteriorating fundamentals and now sits at the 86th percentile of its historical P/S range. This is a momentum-driven move — the market may be front-running a recovery that has not yet appeared in reported numbers.

What would invalidate this read

Operating margin (currently -3,767.07%) would need to stabilize or improve to justify the move. Revenue is declining 94.1% — a trend reversal in the next report would be the key signal to watch. This read is wrong if the next period shows operating metrics turning the corner. At that point the price would be anticipating real improvement rather than running ahead of it.

Performance

Return analysis

Company profile

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments.

CEODipal Doshi

SectorHealthcare

IndustryBiotechnology

Employees152

IPO dateOct 29, 2021

https://www.entradatx.com

Market multiples

Forward P/E—

EV/EBITDA-2.71

Enterprise value$385.84M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth-53.95%

Gross margin (FY2025)83.89%▼16.1ppvs FY2024

Operating margin (FY2025)-613.66%▼636.0ppvs FY2024

ROE-54.09%▼15.0ppvs FY2025

Analyst consensus

RatingBuy

Target price$14.00▲107.41%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.98 · Revenue est $2.13M

View

NASDAQ · TRDA

Entrada Therapeutics, Inc.

Healthcare · Biotechnology

$6.75▼ 2.17% ($0.15)at close

As of 4:00 PM ET

52-week

$5.08$16.45

Market cap

$262.04M

P/E

-1.70

EPS (TTM)

-$3.93

Next earnings

Nov 5, 2026

No multiple

What the market price implies · Reverse DCF

Historical revenue grew by -55.61%/yr over the past 2 years.

Selected forecast · Base scenario

0.8%/yr · actual 10-year annualized revenue growth

Year 1 growth: 0%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$6.75

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.

Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.

Year 1 growth 0% · Ending margin 0% · Discount rate 7.75%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 18, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 20, 2026, 6:24 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Momentum disconnected from fundamentalsModerate confidence

1Y Price: 21.62%Revenue (TTM): -94.1%FCF (TTM): -6.16%P/S: 86th pct

What changed

What the market seems to be pricing

What would invalidate this read

Performance

Return analysis

Company profile

CEODipal Doshi

SectorHealthcare

IndustryBiotechnology

Employees152

IPO dateOct 29, 2021

https://www.entradatx.com

Market multiples

Forward P/E—

EV/EBITDA-2.71

Enterprise value$385.84M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth-53.95%

Gross margin (FY2025)83.89%▼16.1ppvs FY2024

Operating margin (FY2025)-613.66%▼636.0ppvs FY2024

ROE-54.09%▼15.0ppvs FY2025

Analyst consensus

RatingBuy

Target price$14.00▲107.41%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.98 · Revenue est $2.13M

View